NCT04560127View on ClinicalTrials.gov

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Interventions
DRUG

Camrelizumab combination with Apatinib

Apatinib (250mg p.o. q.d.) combined with Camrelizumab (200mg, iv, q2w)

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER